Yabing Nan
State Key Laboratory Of Molecular Oncology, Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, 100021, China
Beijing, 100021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP.
Journal: Blood cancer discovery
Published: January 26, 2026
IRG1/itaconate/NRF2/GSH axis in tumor-associated macrophages drives therapy resistance and immune evasion in BRCA1-deficient breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.
Journal: Nature communications
Published: October 22, 2024
OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: May 03, 2024
Long noncoding RNA LOC646029 functions as a ceRNA to suppress ovarian cancer progression through the miR-627-3p/SPRED1 axis.
Journal: Frontiers of medicine
Published: November 30, 2022
HCP5 prevents ubiquitination-mediated UTP3 degradation to inhibit apoptosis by activating c-Myc transcriptional activity.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 20, 2022
DLGAP1-AS2-Mediated Phosphatidic Acid Synthesis Activates YAP Signaling and Confers Chemoresistance in Squamous Cell Carcinoma.
Journal: Cancer research
Published: February 28, 2022
Last Updated: 09/26/2026